Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis.

Objectives: This study aims to determine whether baseline body mass index (BMI) affects clinical response to tocilizumab (TCZ) after six months of treatment in rheumatoid arthritis (RA) patients.

Patients And Methods: In this prospective study, a total of 52 RA patients (10 males, 42 females; mean age 50.6±12.

Plasma Long Non-Coding RNA Expression Profiles in Patients with Rheumatoid Arthritis.

Background: Recently, long non-coding RNAs (lncRNAs) have attracted substantial attention owing to their unforeseen critical roles in a wide range of biological processes. The aim of our study was to provide an overview of lncRNA expression profiles in plasma of RA patients.

Methods: The Agilent LncRNA + mRNA Human Gene Expression Microarray V4.

The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab.

Background: Emerging evidence indicates that some hematological markers have critical value in evaluating treatment response. This study was performed to determine the clinical value of hemoglobin (Hb), platelet (Plt), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ).

Methods: Fifty-two RA patients receiving TCZ were recruited and followed for 6 months.